Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
暂无分享,去创建一个
Laura A. Petersen | Anita Deswal | Kevin Kennedy | Hani Jneid | Vijay Nambi | Christie M. Ballantyne | H. Jneid | P. Ho | C. Ballantyne | S. Virani | Vijay Nambi | L. Petersen | K. Kennedy | P. Michael Ho | Salim S. Virani | A. Deswal | Mahboob Alam | Ravi S. Hira | Mahboob Alam | Sukhdeep S. Basra | V. Nambi | Ravi S Hira | Sukhdeep S Basra
[1] Susan Smyth,et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.
[2] G. Moneta. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2009 .
[3] P. Toth. Statin Use in Outpatients With Obstructive Coronary Artery Disease , 2012 .
[4] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[5] James F Sallis,et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.
[6] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[7] J. Spertus,et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). , 2011, The American journal of cardiology.
[8] Christopher S Coffey,et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.
[9] M. Roizen. Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials , 2007 .
[10] J. Colwell. Aspirin Therapy in Diabetes , 1997, Diabetes Care.
[11] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[12] H. Jneid,et al. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. , 2014, Journal of the American College of Cardiology.
[13] Seemant Chaturvedi,et al. Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.
[14] 苅尾 七臣,et al. ガイドライン解説 AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease : 2011 update , 2012 .
[15] P. Macfarlane,et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.
[16] B. Yawn,et al. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. , 2009 .
[17] Deepak L. Bhatt,et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). , 2014, Journal of the American College of Cardiology.
[18] H. Jneid,et al. Frequency and practice-level variation in inappropriate and nonrecommended prasugrel prescribing: insights from the NCDR PINNACLE registry. , 2014, Journal of the American College of Cardiology.
[19] J. Travers,et al. Aspirin use and reduced risk of fatal colon cancer. , 1992, The New England journal of medicine.
[20] Deepak L. Bhatt,et al. Socioeconomic disparities in the use of cardioprotective medications among patients with peripheral artery disease: an analysis of the American College of Cardiology's NCDR PINNACLE Registry. , 2012, Journal of the American College of Cardiology.
[21] E. Benjamin,et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiova , 2009, Journal of the American College of Cardiology.
[22] Alastair Baker,et al. Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.
[23] Donna Buchanan,et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. , 2010, Journal of the American College of Cardiology.
[24] John Spertus,et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.
[25] J. Manson,et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. , 1993, Journal of the National Cancer Institute.
[26] H. Goldstein. Multilevel Statistical Models , 2006 .
[27] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[28] Christina M. Mastrangelo,et al. Multilevel Statistical Models, 4th edition , 2011 .
[29] J. Spertus,et al. Treatment differences by health insurance among outpatients with coronary artery disease: insights from the national cardiovascular data registry. , 2013, Journal of the American College of Cardiology.
[30] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[31] E. Benjamin,et al. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention , 2009, Circulation.
[32] Rowena J Dolor,et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.
[33] U. P. S. T. Force. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement , 2009, Annals of Internal Medicine.
[34] B. Yawn,et al. Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2007, Annals of Internal Medicine.
[35] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.